铜绿假单胞菌感染的流行趋势和治疗进展.pptVIP

铜绿假单胞菌感染的流行趋势和治疗进展;主要内容;

PseudomonasAeruginosa(PA);2、致病性;定义;

铜绿假单胞菌3年耐药监测成果分析;2023年中国CHINET铜绿假单胞菌耐药性监测;Mohnarin2023年度全国细菌耐药监测;2023年中国CHINET细菌耐药性监测;2023年中国CHINET细菌耐药性监测;AntimicrobialResistanceAmongClinicalIsolatesFromTheChineseMeropenemSurveillanceStudy(CMSS),2023–2023（美罗培南敏感性监测(CMSS)报告）;革兰阴性杆菌耐药情况研究

———2023中国美罗培南敏感性监测(CMSS)报告;中国重症监护病房细菌耐药性监测研究;中国重症监护病房革兰阴性菌耐药性连续7年监测研究;王辉，中华医学杂志，83（5）：385-390.;ICU环境及护理人员与发生VAP旳关系;Nationalsurveillanceofantimicrobialresistanceinpseudomonasaeruginosaisolatesobtainedfromintensivecareunitpatientsfrom1993to2023.;Emergenceofextensivelydrug-resistantandpandrug–resistantgram-negativebacilliinEurope;感染PA旳危险原因;MDR-PA旳耐药机制;治疗疗程;

PredictorsOf30DayMortalityAmongPatientsWithPseudomonasAeruginosaBloodstreamInfections:ImpactOfDelayedAppropriateAntibioticSelection;;

;针对MDR-PA旳联合治疗方案;针对MDR-PA旳联合治疗方案;联合治疗;3药联合治疗;Fosfomycinforthetreatmentofinfectionscausedbymultidrug-resistantnon-fermentingGram-negativebacilli:asystematicreviewofmicrobiological,animalandclinicalstudies.

Insixclinicalstudies,33patientswithMDRP.aeruginosainfec-tions(mainlypulmonaryexacerbationsofcystic?brosis)receivedfosfomycin(25/33incombinationwithotherantibiotics);91%ofthepatientsclinicallyimproved.Inconclusion,fosfomycincouldhavearoleasatherapeuticoptionagainstMDRP.aeruginosainfections.Furtherresearchisneededtoclarifythepotentialutilityofthisagent.

;Currenttreatmentofpseudomonalinfectionsintheelderly.

Intheelderly,inadditiontomakingdosemodificationsthatareneededbecauseoflossofrenalfunction,theprescribershouldbemorecautiousabouttheuseofaminoglycoside-containingregimens,possiblyreplacingthemwithacombinationofquinoloneandabeta-lactam,notwithstanding